| Stem definition | Drug id | CAS RN |
|---|---|---|
| ribofuranyl-derivatives of the "pyrazofurin" type | 3363 | 50924-49-7 |
None
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 51 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 0.91 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Osteonecrosis | 42.72 | 31.46 | 16 | 1075 | 24514 | 63463417 |
| Pharyngitis | 38.23 | 31.46 | 14 | 1077 | 20129 | 63467802 |
| Hyperuricaemia | 36.99 | 31.46 | 10 | 1081 | 5360 | 63482571 |
| Hyperlipidaemia | 34.92 | 31.46 | 13 | 1078 | 19558 | 63468373 |
| Iron deficiency anaemia | 34.67 | 31.46 | 13 | 1078 | 19956 | 63467975 |
| Angiocentric lymphoma | 31.92 | 31.46 | 6 | 1085 | 625 | 63487306 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cytomegalovirus infection | 40.45 | 29.87 | 20 | 1906 | 42624 | 79699838 |
| Pharyngitis | 38.81 | 29.87 | 16 | 1910 | 22359 | 79720103 |
| N-telopeptide urine increased | 36.96 | 29.87 | 5 | 1921 | 42 | 79742420 |
| Osteonecrosis | 36.85 | 29.87 | 17 | 1909 | 31078 | 79711384 |
| Kidney transplant rejection | 34.86 | 29.87 | 12 | 1914 | 10234 | 79732228 |
| Iron deficiency anaemia | 33.46 | 29.87 | 15 | 1911 | 25657 | 79716805 |
| Hyperlipidaemia | 33.23 | 29.87 | 15 | 1911 | 26078 | 79716384 |
| Hyperuricaemia | 33.20 | 29.87 | 12 | 1914 | 11787 | 79730675 |
None
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D000903 | Antibiotics, Antineoplastic |
| MeSH PA | D000962 | Antimalarials |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D007166 | Immunosuppressive Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| CHEBI has role | CHEBI:149553 | anticoronaviral drug |
None
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.79 | acidic |
| pKa2 | 11.55 | acidic |
| pKa3 | 11.83 | acidic |
| pKa4 | 12.51 | acidic |
| pKa5 | 13.19 | acidic |
| pKa6 | 3.13 | Basic |
None
None
None
| ID | Source |
|---|---|
| D01392 | KEGG_DRUG |
| C0128608 | UMLSCUI |
| CHEBI:31858 | CHEBI |
| MZR | PDB_CHEM_ID |
| CHEMBL245019 | ChEMBL_ID |
| DB12617 | DRUGBANK_ID |
| C010052 | MESH_SUPPLEMENTAL_RECORD_UI |
| 104762 | PUBCHEM_CID |
| 5120 | INN_ID |
| 4JR41A10VP | UNII |
| 772627008 | SNOMEDCT_US |
None